[en] The two types of endometrial carcinomas are preceded by precancerous lesions. Type I endometrial carcinomas are most commonly encountered in perimenopausal women with the classical risk factors associated with estrogen exposure: obesity, multiparity, diabetes, estrogen treatment, ... Hyperplasia (simple, followed by complex forms without cellular atypias and subsequently by complex hyperplasias with cellular transformation) precede such cancers. Estrogens exert a promoting effect on these lesions but do not initiate them. Progesterone and progestins exert a preventive and protective effect. However, the progressive loss of steroidal receptors is correlated to the progression of tissular anomalies and to the onset of cytogenetic anomalies and to mutations of p53 anti-oncogene. The preventive role of progestin is well established, but their curative beneficial effect on atypical precursors forms of endometrial cancers and on endometrial carcinomas remains controversial. The second type of endometrial cancer appears during the postmenopause and is characterized by an increased invasiveness and a poor prognosis, devoid of identifiable risks factors, these aggressive cancers are not preceded by hormone-sensitive precancerous lesions, but by an intra-epithelial endometrial carcinoma. This lesion appears most often in an atrophic endometrium. Finally, the two types of precancerous states are characterized by distinct gene anomalies suggesting two different pathogenic mechanisms of cancerisation.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Gilliquet, A.
Nondonfaz, N.
Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
Kridelka, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie et obstétrique
Dubois, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
Language :
French
Title :
Les états précancéreux de l'endomètre: aspects hormonaux
Alternative titles :
[en] Precancerous States of the Endometrium: Hormonal Aspects
SHERMAN M. E., STURGEON S., BRINTON L., KURMAN R.J. - Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J. Cell. Biochem., 1995, 23, 160 -164.
BURKE T. W., TORTOLERO -LUNA G., MALPICA A., BAKER V.V., WHITTAKER L., JOHNSON E., POLLEN MITCHELL M. - Endometrial hyperplasia and endometrial cancer. In: M. Follen Mitchell, D. Schottenfeld, W. Ki Hong. « Gynecologic Cancer Prevention ». Obstetrics and Gynecology - Clinics of North America. Philadelphia, USA: W.B. Saunders Company, 1996, vol. 23, 2, 411 -456.
GEPPERT M., SMYCZEK -GARGYA B., MENTON M. - Diagnosis and follow -up of atypical hyperplasia of corpus endometrium. A critical methodological investigation. Zentralbl. Gynakol., 1993, 115, 492 -494.
MENCAGLIA L. - Hysteroscopy and adenocarcinoma. In: A.M. Siegler. « Hysteroscopy ». Obstetrics and Gynecology - Clinics of North America. Philadelphia, USA: W.B. Saunders Company, 1995, vol. 22, 3, 573 -579.
MAGE G., BOURNAZEAU J. A., CANIS M. et coll. - Traitement préventif et curatif du cancer de l'endomètre. In: « Collège National des Gyécologues Obstétriciens Français. Mises à jour en Gynécologie -Obstétrique ». Paris, Vigot, 1994, 359 -393.
HERTIG A. T., SOMMERS S.C. - Genesis of endometrial carcinoma. Study of prior biopsies. Cancer, 1949, 2, 964 -971.
BERGERON C., FERENCZY A., SHYAMALA G. - Distribution of estrogen receptors in various cell types of normal, hyperplastic, and neoplastic human endometrial tissues. Lab. Invest., 1988, 58, 338 -345.
FERENCY A., BERGERON C. - Endometrial hyperplasia in advances. In: D. Lowe, H. Fox. « Gynecological Pathology ». New York: Churchill Livingstone, 1992, 207 -234.
ADLER L. M., MUTCH D.G. - Endometrial hyperplasia. In: D.A. Metzger. « The Endometrium ». Infertility and Reproductive Medicine - Clinics of North America. Philadelphia, USA: W.B. Saunders Company, 1995, vol. 6, 2, 441 -453.
ROSE P. O. - Endometrial carcinoma. New Engl. J. Med., 1996, 335, 640 -649.
FERENCZY A., GELFAND M. The biologic significance of cytologic atypia in progesterone -treated endometrial hyperplasia. Am. J. Obstet. Gynecol., 1989, 160, 126 -131.
LINDAHL B., WILLEN R. - Spontaneous endometrial hyperplasia. A prospective, 5 year follow -up of 246 patients after abrasio only, including 380 patients followed -up for 2 years. Anticancer Res., 1994, 14, 2141 -2146.
JOVANOVIC A. S., BOYNTON K.A., MUTTER G.L. - Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res., 1996, 56, 1917 -1921.
BOYD J. - Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma. In: J. Huff, J. Boyd, J.C. Barrett. « Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences ». Wiley -Liss, Inc., 1996, 151 -173.
Oral contraceptive use and the risk of endometrial cancer: the Centers for Disease Control Cancer and Steroid Hormone Study. JAMA, 1983, 249, 1600 -1604.
PUNNONEN R., MATTILA J., KUOPPALA T. et coll. - DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma. J. Cancer Res. Clin. Oncol., 1993, 119, 426.
PERSSON I., ADAMI H. O., BERGKVIST L. et coll. - Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br. Med. J., 1989, 298, 145.
BERESFORD S. A. A., WEISS N.S., VOIGT L.F., MCKNIGHT B. - Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. The Lancet, 1997, 349, 458 -461.
COMERCI J. T. JR., FIELDS A.L., RUNOWICZ C.D., GOLDBERG G.L. - Continuous low -dose combined hormone replacement therapy and the risk of endometrial cancer. Gynecol. Oncol., 1997, 64, 425 -430.
MECKE H., LÜTTGES J., LEHMANN -WILLENBROOCK E., KUNSTMANN P., FREYS I. - Treatment of precursors of endometrial cancer. Gynecol. Obstet. Invest., 1994, 37, 130 -134.
MARTIN -HIRSCH P. L., MILFORD R.D. - Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta -analyses of published randomised controlled trials. Eur. J. Obstet. Gynecol. Reprod. Biol., 1996, 05, 201 -207.
ENOMOTO T., FUJITA M., INOUE M., RICE J.M., NAKAJIMA R., TANIZAWA O., NOMURA T. Alterations of the p53 tumor suppressor gene and its association with activation of the c -K -ras -2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res., 1993, 53, 1883 -1888.
SHERMAN M. E., BUR M.E., KURMAN R.J. - p 53 protein expression in endometrial tumors and their putative precursors. Mol. Pathol., 1995, 8, 97A.
KOHLER M. F., BERCHUCK A., DAVIDOFF A.M. - Overexpression and mutation of p 53 in endometrial carcinoma. Cancer Res., 1992, 52, 1622 -1627.
BUR M. E., PERLMAN C., EDELMANN L., FEY E., ROSE P.O. - p 53 expression in neoplasms of the uterine corpus. Am. J. Clin. Pathol., 1992, 98, 81 -87.